Fresh analysis indicates that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional diet and exercise programs.
Findings released in a major health publication points out that while obese individuals can lose about a fifth of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"Users using such treatments must be aware of the danger of rapid weight regain when the treatment ends," warns researcher Dr. Susan Jebb.
That rate of regain suggests a reversion to starting weight within about a year and a half.
Comparing Treatments
The analysis, which examined 37 of studies involving thousands of patients, compared the results of these new drugs with conventional dieting.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually see a slower weight regain—approximately 100 grams monthly—after stopping.
Understanding the Quick Rebound
Experts believe the mode of action of the jabs explains the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 levels several times higher than normal could lead to the system to produce less of its endogenous hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to appetite is no longer kept in check, making binge eating much more probable."
A Chronic Condition?
The NHS recommend the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals say that, given the high risk of weight regain, the treatment might need to be life-long.
This view is echoed by drug manufacturers, who state that the findings "underscore the long-term nature of excess weight," similar to managing diseases like high blood pressure.
User Testimonies
Users who have discontinued the medication describe a powerful resurgence of cravings.
"I experienced a switch flipping and you become extremely hungry," recalled an individual.
The struggle is compounded if users have not established lasting dietary or behavioural changes during treatment.
Widespread Use
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the past year, with demand being substantial.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers caution that while these medications are effective agents for weight loss, they are not a magic fix and lasting health benefits hinges on combined behavioural support.
